Systemic sclerosis-associated interstitial lung disease (SSc-ILD)
- Monitor lung function and progression closely
- Mycophenolate is a common first immunosuppressive therapy
- Nintedanib slows FVC decline
- Tocilizumab can preserve lung function in selected inflammatory disease
- Avoid high-dose glucocorticoids because renal-crisis risk
- Early transplant referral for advanced progressive disease
Use at a glance
- Monitor lung function and progression closely
Escalation / refractory disease
- Mycophenolate is a common first immunosuppressive therapy
- Nintedanib slows FVC decline
- Early transplant referral for advanced progressive disease
Choosing treatment
- Tocilizumab can preserve lung function in selected inflammatory disease
Safety / pitfalls
- Avoid high-dose glucocorticoids because renal-crisis risk
Self-check
- What is a common first immunosuppressive therapy for SSc-ILD?
Mycophenolate.
- Why should high-dose glucocorticoids be avoided in SSc-ILD?
Renal-crisis risk.
Drugs used for this (1)
All clinical uses · Open the interactive console ↗
